Helixmith Shareholders Fail In Bid To Oust Top Management
Trials, Stock Recovery Now Key
Executive Summary
Relief for Helixmith’s management as voting at recent shareholders' meeting failed to remove top executives, including the South Korean biotech’s founder and CEO, following recent setbacks. But the future of the board may now depend largely on the success of the ongoing clinical trials for lead assets and stock price recovery.